Results 211 to 220 of about 28,689 (318)

REACH2: ruxolitinib for refractory aGvHD [PDF]

Nature Reviews Clinical Oncology, 2020
openaire   +3 more sources

Use of Extracorporeal Photopheresis Treatment Over Time (2001–2023) in Alberta, Canada: A Retrospective Cohort Study

Health Science Reports, Volume 8, Issue 10, October 2025.
Louis Girard, Sylvia Aponte‐Hao, Jason R. Randall, Karen J. B. Martins, Huong Luu, Khanh Vu, Tyler Williamson, Scott W. Klarenbach   +7 more
wiley   +1 more source

Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine

European Journal of Haematology, Volume 115, Issue 4, Page 380-390, October 2025.
ABSTRACT JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers.
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, Jürgen Wehmeyer, Eyck von der Heyde, Hans Tesch, Benedikt Gröschl, Petra Bachhuber, Susanne Großer, Michael Koehler, Heike L. Pahl   +15 more
wiley   +1 more source

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study. [PDF]

Future Oncol
Aruga Y, Hongo W, Lu W.
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

Contraception in Myeloproliferative Neoplasms: A Pharmacological Review

European Journal of Haematology, Volume 115, Issue 4, Page 344-348, October 2025.
ABSTRACT Myeloproliferative neoplasms (MPNs) are chronic hematologic disorders characterized by clonal proliferation of myeloid lineage cells, commonly driven by JAK2 mutations, and associated with significant thrombotic and hemorrhagic complications.
Awni Alshurafa, Maria Benkhadra, Anas M. Babiker, Wafa M. Mohammed, Mohamed A. Yassin   +4 more
wiley   +1 more source

The Mechanisms of Resistance to JAK Inhibitors in Lymphoid Leukemias: A Scoping Review of Evidence from Preclinical Models and Case Reports. [PDF]

Int J Mol Sci
Martínez Anaya D, Coyotecatl MV, Navarrete Meneses MDP, Enríquez Flores S, Pérez-Vera P.   +4 more
europepmc   +1 more source

Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib [PDF]

, 2019
DiPersio, John F., Goldsmith, Scott R., Saif Ur Rehman, Sana, Shirai, Cara L., Vij, Kiran   +4 more
core   +1 more source

Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials [PDF]

, 2018
Madan Jagasia, Robert Zeiser, Michael Arbushites, Patricia Delaite, Brian Gadbaw, Nikolas von Bubnoff   +5 more
openalex   +1 more source

Identification of a Small Secretoneurin Derivative That Inhibits CaMKIIδ Activity

Journal of Cellular and Molecular Medicine, Volume 29, Issue 20, October 2025.
ABSTRACT Ventricular arrhythmias, a major cause of sudden cardiac death, are driven by Ca2+ imbalance in cardiac myocytes, often linked to the overactivation of CaMKIIδ (Ca2+/calmodulin‐dependent protein kinase II delta). As such, inhibiting CaMKIIδ represents a promising therapeutic strategy. Based on our previous finding that native secretoneurin (SN)
Ilde Rugolo, Xin Shen, Thea Parsberg Støle, Anna Bergan‐Dahl, Ornella Manfra, Marianne Lunde, Geir Christensen, Bjørn Dalhus, William E. Louch, Anett H. Ottesen, Helge Røsjø, Cathrine Rein Carlson   +11 more
wiley   +1 more source